Wyeth 10Q 2008 Q1 Quarterly report | WYE Filing

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: AAA, AB, Abbott, abdominal, aboutPRISTIQ, AF, aggressive, ALAVERTand, andCENTRUM, andPONDIMINdiet, andPROTONIX, andScroggin, approvedPRISTIQ, arbitration, arrangement, artificially, Asian, AstraZeneca, AWP, baseline, bioavailability, bone, bosutinib, bothEFFEXORand, broad, bromide, build, calicheamicin, CE, China, chronic, Cir, citizen, colectomy, complaint, comply, concurrence, conference, Cook, corroborated, Ct, CYPHER, decongestant, decreasedPROTONIX, default, Deferral, derivative, derived, dysfunction, Endocrinology, endometrial, entity, ERISA, excellence, expansion, experience, expertise, exploring, exposure, factor, factual, failed, Florence, follicular, forADVIL, forEFFEXORand, forREFACTO, forRELISTOR, forXYNTHAin, fromALTACE, fromEFFEXOR, fundamentally, Gynecological, harm, heavy, hemophilia, higherEFFEXOR, highlighted, hyperplasia, identical, Impax, inflated, inotuzumab, inPRISTIQ, inScroggin, intensifying, intention, intercompany, intravenousRELISTORfor, IPD, Italy, kinase, knew, launchedTYGACIL, launchRELISTORin, laxative, leukemia, levonorgestrel, liable, linking, liquidity, low, lowerPROTONIXmarketing, loyalty, lymphoma, MAA, marginPROTONIX, MDD, modulator, monetary, monitoring, Monmouth, Mortality, multiplied, nanofiltration, netincreased, network, Noncontrolling, nonfinancial, notification, ofALAVERT, ofRELISTOR, ofROBITUSSIN, oncology, orPREMPRO, OTC, ozogamicin, Paragraph, parent, Parenteral, People, percent, postponed, prejudice, private, prohibiting, protocol, prudence, purification, pursue, putative, quality, quoted, recall, receptor, recombinant, recover, recovering, refund, relevance, relevant, renewed, repair, Retirement, retrospectively, ROBITUSSIN, severalROBITUSSIN, sexual, sheet, shippingPRISTIQ, Singapore, sought, source, statewide, Super, supportingTYGACIL, surgical, survive, targeted, technology, thatPREVNAR, thePROTONIXfamily, toAPRELA, top, toxicity, TPMI, traditional, transforming, transparency, undergone, unobservable, uphold, Upjohn, VMS, voluntarily, Watson, Weekly, withdrawn, withdrew, WJM, workforce, WRW, XYNTHA, young

Removed: accelerated, Accenture, acceptability, acceptable, affirmed, agency, aimed, analyze, andPONDIMIN, anticipation, assumed, bifeprunox, booster, called, capitalize, carcinoma, category, cell, choose, claiming, clarity, column, component, confirmation, conform, continually, converted, create, culture, declaratory, declined, deemed, depreciation, designation, dismissing, divestiture, dosage, earn, education, efficiency, efficient, EMEA, encouraging, enhanced, enrolled, Enterprise, establishment, exit, expanded, expedite, experienced, expert, extend, fast, fee, FIN, focusing, forEFFEXORandEFFEXOR, forENBREL, forLYBREL, formal, forPREVENAR, forPRISTIQfor, function, gastrointestinal, Germany, goal, Guayama, highest, holding, hospitalization, implementation, improving, inception, inclusion, inEFFEXOR, informed, innovation, inspection, interpretation, introducing, inTYGACIL, investigated, inZOSYN, Japan, JD, jurisdiction, LA, law, LLC, local, master, Member, merit, Mexico, mitigation, modest, move, multiple, NIP, notice, objective, observed, ofPREMPROorPREMARIN, ofPREVNAR, ofProvision, opportunity, Organization, outsourced, paving, potentially, PPI, Pressure, productINDERAL, productive, prolong, proprietary, Puerto, ranked, receive, recognized, reflected, regardingALTACE, regardingEFFEXOR, reimbursed, renal, replacing, reported, residing, responsibility, Restated, retained, routine, SAP, schedule, schizophrenia, select, Solvay, Springboard, standalone, succeed, supplier, Supreme, system, tailoring, Takeda, testing, theProvision, thrive, toTYGACIL, track, transition, unrealized, unrecognized, venture, wherePRISTIQ, yield, ZOSYNexpired


By:		/s/ Bernard Poussot
		Bernard Poussot
		President and Chief Executive Officer

Wyeth (WYE) Inactive 10-Q2008 Q1 Quarterly report

Content analysis